Abstract:ABSTRACT The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, >20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients. IMPORTANCE Dengue virus (DENV) threatens up to 2.5 billion people and is now spreading in many regions in the world where it was not previously endemic. While there are several promising vaccine candidates in clinical trials, approved vaccines or antivirals are not yet available. Here we describe the identification and characterization of a spiropyrazolopyridone as a novel inhibitor of DENV by targeting the viral NS4B protein. The compound potently inhibits two of the four serotypes of DENV (DENV-2 and -3) both in vitro and in vivo. Our results validate, for the first time, that NS4B inhibitors could potentially be developed for antiviral therapy for treatment of DENV infection in humans.

Structure-guided Discovery of a Novel Non-peptide Inhibitor of Dengue Virus NS2B-NS3 Protease.

Discovery Of Novel Small Molecule Inhibitors Of Dengue Viral Ns2b-Ns3 Protease Using Virtual Screening And Scaffold Hopping

Design, synthesis and biological activity evaluation of novel allosteric inhibitors of the DENV NS2B–NS3 protease

Identification of a Novel Inhibitor of Dengue Virus Protease through Use of a Virtual Screening Drug Discovery Web Portal

Discovery of Novel Dengue Ns2b/Ns3 Protease Inhibitors Using Pharmacophore Modeling and Molecular Docking Based Virtual Screening of the Zinc Database

In silico fragment-based design and pharmacophore modelling of therapeutics against dengue virus envelope protein

Computational design and in vitro assay of lantadene-based novel inhibitors of NS3 protease of dengue virus

Novel Antiviral Phytochemicals Against Dengue Virus 2 NS2B‐NS3 Protease: An In Silico Drug Development Approach

Identification of Novel Thiadiazoloacrylamide Analogues As Inhibitors of Dengue-2 Virus NS2B/NS3 Protease.

Discovery of highly potent DENV NS2B-NS3 covalent inhibitors containing a phenoxymethylphenyl residue

Identification of Fused Bicyclic Derivatives of Pyrrolidine and Imidazolidinone As Dengue Virus-2 NS2B-NS3 Protease Inhibitors

1 Identification of lead-like and non-lead-like inhibitors for dengue virus NS 2 B / NS 3 protease by tryptophan fluorescence

3D-QSAR Pharmacophore-Based Virtual Screening, Molecular Docking and Molecular Dynamics Simulation Toward Identifying Lead Compounds for NS2B-NS3 Protease Inhibitors.

Design, Synthesis, Evaluation and Molecular Dynamics Simulation of Dengue Virus NS5-RdRp Inhibitors

Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Predicting repurposed drugs targeting the NS3 protease of dengue virus using machine learning-based QSAR, molecular docking, and molecular dynamics simulations

Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3 '-Indoline]-2 ',5(3H)-Dione Analogues As Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection

Discovery and SAR Studies of Methionine–proline Anilides As Dengue Virus NS2B-NS3 Protease Inhibitors

Discovery and optimization of 2,4-diaminoquinazoline derivatives as a new class of potent dengue virus inhibitors.

Antiviral Drug Discovery with an Optimized Biochemical Dengue Protease Assay: Improved Predictive Power for Antiviral Efficacy

Discovery of Dengue Virus Ns4b Inhibitors